Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23, 2016 and the company has presently approximately 8,000 shareholders.
For further information, please contact:
Marie Svensson, CFO
Tel: +46 46 540 82 03